Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10,13-trimethoxy- | 38691-93-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10,13-trimethoxy-
• 英文别名: 16,17,21-trimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
• CAS: 38691-93-9
• 化学式: C21H20NO5+
• 分子量: 366.4
• InChiKey: MLENXYPZCCNDEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  50
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2070926A1

  公开（公告）日：2009-06-17

  The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance.

  本发明提供了由下式表示的13,13a-二氢小檗碱衍生物或其生理上可接受的盐、由其组成的药物组合物及其用途。13,13a-二氢小檗碱衍生物具有促进肌肉细胞吸收葡萄糖的活性，整体动物试验表明，本发明化合物具有改善糖耐量和胰岛素抵抗、促进减肥、缓解脂肪肝等作用。因此，本化合物可用于治疗胰岛素抵抗引起的糖尿病、肥胖症、脂肪肝及其并发症。
• Method and composition for controlling oral pathogens
  申请人：Wu D. Christine

  公开号：US20070098649A1

  公开（公告）日：2007-05-03

  A composition and method of controlling oral and other human pathogens is disclosed. The composition and method utilize an antimicrobial or antibiotic and a berberine as active agents to treat mammals, including humans.